Ryan Confer, President and Chief Executive Officer at Genprex, sat down with the Marathon Money podcast to discuss the Company’s pipeline of gene therapies for cancer and diabetes. Watch the interview here: https://www.youtube.com/watch?v=blIpam7eBTc
Original article: Genprex – Developing Novel Gene Therapies in Cancer with Tumor Suppressor Genes and Diabetes Converting Alpha Cells into Beta Cells to Produce Insulin (CEO CFO Magazine)
Original article: Acclaim-3 Dosing Begins: Quaratusugene Ozeplasmid/Atezolizumab in ES-SCLC (Targeted Oncology)
Genprex's Chief Financial Officer, Ryan Confer, shares his insight on partnering with academic institutions, the benefits, and best practices
Diabetes is the most expensive chronic illness in the U.S., with $1 of every $4 in healthcare costs going to care for diabetics. The National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP) estimates that $237 billion is spent directly on diabetes-related medical costs every year, while another $90 billion is lost each year due to reduced productivity associated with diabetes.
Bell2Bell’s latest podcast features Chairman, President and CEO Rodney Varner and CFO Ryan Confer of Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes. In this interview, Varner and Confer discuss the journeys that led them to Genprex and the promise of the company’s drug development pipeline.
Bell2Bell’s latest podcast features Dr. Mark Berger, Chief Medical Officer of Genprex Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes.
On the heels of the release of recent positive safety and early efficacy data related to the phase 1 portion of its Acclaim-1 phase 1/2 clinical trial for non-small cell lung cancer evaluating REQORSA in combination with Tagrisso, Genprex has released a new patient video featuring an NSCLC patient from the phase 1 portion of its Acclaim-1.
Genprex Inc., a clinical-stage gene therapy company, is focused on developing for these patients with serious medical conditions and unmet need new and better treatment options that are life-changing.
Reprogramming the course of cancer and diabetes, Austin-based Genprex is on the cutting edge of technologies to address the biggest health concerns